Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John Ravits

Showing results (91-100 of 102) with videos related to

Pageof 11
Sort By:
Cell|June 23, 2026
An emergent disease-associated motor neuron state precedes cell death in ALSOlivia Gautier, Jacob A Blum, Thao P Nguyen, et al.
The New England Journal of Medicine|July 9, 2020
Phase 1-2 Trial of Antisense Oligonucleotide Tofersen for <i>SOD1</i> ALSTimothy Miller, Merit Cudkowicz, Pamela J Shaw, et al.
Translational Neurodegeneration|October 29, 2025
Shared burden of ultra-rare genetic variants across a spectrum of motor neuron diseasesGang Wu, Wenan Chen, Joanne Wuu, et al.
The Lancet. Neurology|July 26, 2024
Safety, tolerability, and pharmacokinetics of antisense oligonucleotide BIIB078 in adults with C9orf72-associated amyotrophic lateral sclerosis: a phase 1, randomised, double blinded, placebo-controlled, multiple ascending dose studyLeonard H van den Berg, Jeffrey D Rothstein, Pamela J Shaw, et al.
Nature Neuroscience|November 23, 2023
Stathmin-2 loss leads to neurofilament-dependent axonal collapse driving motor and sensory denervationJone López-Erauskin, Mariana Bravo-Hernandez, Maximiliano Presa, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 31, 2013
Targeted degradation of sense and antisense C9orf72 RNA foci as therapy for ALS and frontotemporal degenerationClotilde Lagier-Tourenne, Michael Baughn, Frank Rigo, et al.
EMBO Molecular Medicine|December 3, 2020
Machine learning suggests polygenic risk for cognitive dysfunction in amyotrophic lateral sclerosisKaterina Placek, Michael Benatar, Joanne Wuu, et al.
Neurobiology of Aging|December 15, 2022
Whole genome sequencing analysis reveals post-zygotic mutation variability in monozygotic twins discordant for amyotrophic lateral sclerosisGijs H P Tazelaar, Paul J Hop, Meinie Seelen, et al.
JAMA Neurology|July 6, 2026
Antisense Oligonucleotide Tofersen Distribution in the Central Nervous System of SOD1-ALS Autopsy Tissue DonorsAmanda J Guise, Monica Thanawala Sellon, Shanu F Roemer, et al.
Neuron|April 27, 2016
Gain of Toxicity from ALS/FTD-Linked Repeat Expansions in C9ORF72 Is Alleviated by Antisense Oligonucleotides Targeting GGGGCC-Containing RNAsJie Jiang, Qiang Zhu, Tania F Gendron, et al.
Pageof 11

Showing results (91-100 of 102) with videos related to

Sort By:
Pageof 11
Cell|June 23, 2026
An emergent disease-associated motor neuron state precedes cell death in ALSOlivia Gautier, Jacob A Blum, Thao P Nguyen, et al.
The New England Journal of Medicine|July 9, 2020
Phase 1-2 Trial of Antisense Oligonucleotide Tofersen for <i>SOD1</i> ALSTimothy Miller, Merit Cudkowicz, Pamela J Shaw, et al.
Translational Neurodegeneration|October 29, 2025
Shared burden of ultra-rare genetic variants across a spectrum of motor neuron diseasesGang Wu, Wenan Chen, Joanne Wuu, et al.
The Lancet. Neurology|July 26, 2024
Safety, tolerability, and pharmacokinetics of antisense oligonucleotide BIIB078 in adults with C9orf72-associated amyotrophic lateral sclerosis: a phase 1, randomised, double blinded, placebo-controlled, multiple ascending dose studyLeonard H van den Berg, Jeffrey D Rothstein, Pamela J Shaw, et al.
Nature Neuroscience|November 23, 2023
Stathmin-2 loss leads to neurofilament-dependent axonal collapse driving motor and sensory denervationJone López-Erauskin, Mariana Bravo-Hernandez, Maximiliano Presa, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 31, 2013
Targeted degradation of sense and antisense C9orf72 RNA foci as therapy for ALS and frontotemporal degenerationClotilde Lagier-Tourenne, Michael Baughn, Frank Rigo, et al.
EMBO Molecular Medicine|December 3, 2020
Machine learning suggests polygenic risk for cognitive dysfunction in amyotrophic lateral sclerosisKaterina Placek, Michael Benatar, Joanne Wuu, et al.
Neurobiology of Aging|December 15, 2022
Whole genome sequencing analysis reveals post-zygotic mutation variability in monozygotic twins discordant for amyotrophic lateral sclerosisGijs H P Tazelaar, Paul J Hop, Meinie Seelen, et al.
JAMA Neurology|July 6, 2026
Antisense Oligonucleotide Tofersen Distribution in the Central Nervous System of SOD1-ALS Autopsy Tissue DonorsAmanda J Guise, Monica Thanawala Sellon, Shanu F Roemer, et al.
Neuron|April 27, 2016
Gain of Toxicity from ALS/FTD-Linked Repeat Expansions in C9ORF72 Is Alleviated by Antisense Oligonucleotides Targeting GGGGCC-Containing RNAsJie Jiang, Qiang Zhu, Tania F Gendron, et al.
Pageof 11